Table 1.
IPA Disease and Biofunction downstream effect analysis.
| Diseases and Biofunction | # molecules |
|---|---|
|
Movement Disorders ACAT1, AHCYL1, AK1, ALB, ALDH5A1, ATP1A2, ATP1A3, ATP1B1, ATP1B2, ATP50, ATP6V1E1, Cdc42, CKB, CNP, DPYSL3, ENO2, ENO3, EPB41L3, GAPDH, GNAO1, GPD1, HSP90AA1, MAPT, MBP, MOG, NDRG2, NEFL, PEBP1, PGK1, PLP1, PPIA, PRDX2, RHOG, SLC1A2, SNCA, SNCB, SNCG, SOD2, SYN1, TPI1, TUBB1, MTUBB3 |
42 |
|
Neurodegeneration ATP1B1, CNP, DPYSL2. DPYSL3, GAPDH, MAPT, NEFM, PLP1, RAB1A, SLC1A2, SNCA, SNCB, SOD2 |
13 |
|
Paralysis ATP1A2, ATP1A3, ATP1B2, HSPD1, MAPT, MBP, MOG, NEFM, PLP1, SLC1A2, SLC25A4, SNCA, TUBB1, TUBB3 |
14 |
|
Glyosis ALDH5A1, MAPT, MOG, PLP1, S100B, SNCA, SOD2 |
7 |
The table summarizes the predicted relation between molecules modulated in our datasets and biologica function or disease strictly related to SCI. Proteins more espressed in SAL (underlined) and in DHA (bold) spinal tissues are reported.